Yayınlar & Eserler

Makaleler 195
Tümü (195)
SCI-E, SSCI, AHCI (162)
SCI-E, SSCI, AHCI, ESCI (162)
Scopus (171)
TRDizin (30)
Diğer Yayınlar (4)
Hakemli Bilimsel Toplantılarda Yayımlanmış Bildiriler 216

9. PERİFERİK T HÜCRELİ LENFOMA TANILI HASTALARIN ANALİZİ: TEK MERKEZ DENEYİMİ

50.Ulusal Hematoloji Kongresi, Antalya, Türkiye, 29 Ekim - 02 Kasım 2024, ss.136-137, (Tam Metin Bildiri)

19. ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN RELAPS/REFRACTORY LYMPHOMA PATIENTS: A SINGLE CENTER EXPERIENCE

49th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation, ELECTR NETWORK, 23 - 26 Nisan 2023, ss.457-458, (Özet Bildiri) identifier

20. Allogeneic Stem Cell Transplantation for Relapsed and/or Refractory Hodgkin Lymphoma: A Multicenter Real World Experience

65th Annual Meeting of the American-Society-of-Hematology (ASH), California, Amerika Birleşik Devletleri, 9 - 12 Aralık 2023, cilt.142, (Özet Bildiri) identifier

21. ALPHA-1-ANTITRYPSIN EXPERIENCE FOR STEROID-RESISTANT ACUTE GRAFT-VERSUS-HOST DISEASE

49th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation, ELECTR NETWORK, 23 - 26 Nisan 2023, ss.301-302, (Özet Bildiri) identifier

22. EXTERNAL VALIDATION OF THREE EXISTING EARLY MYELOMA RELAPSE SCORES (BY EBMT, CIBMTR, AND GIMEMA) IN A SINGLE CENTER SHOWS MAJOR DIFFERENCES

The 49th Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians, Paris, Fransa, 23 Nisan 2023, cilt.58, ss.107, (Tam Metin Bildiri)

24. The Impact of CD34+Cell and Immunefector Cell Dose on Transplant Outcomes

64th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Louisiana, Amerika Birleşik Devletleri, 10 - 13 Aralık 2022, cilt.140, ss.12673-12674, (Özet Bildiri) Creative Commons License identifier

26. Prophylactic defibrotide is effective for acute graft versus host disease as well as sinusoidal obstructive syndrome

48th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), Amerika Birleşik Devletleri, 19 - 22 Mart 2022, (Tam Metin Bildiri)

27. Allogeneic hematopoietic stem cell transplantation in elderly patients with acute myeloid leukemia: A single center experience

48th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT), Amerika Birleşik Devletleri, 19 - 22 Mart 2022, (Tam Metin Bildiri)

28. İKİNCİ ALLOJENEİK KÖK HÜCRE NAKLİ: GERÇEK YAŞAM VERİSİ

14. Ulusal kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, 10 Mart 2022, (Tam Metin Bildiri)

34. HODGKİN LENFOMA TANILI HASTALARDA EKSTRANODAL TUTULUM VE YENİ TEDAVİLER

47. Ulusal Hematoloji Kongresi , Antalya, Türkiye, 4 - 07 Kasım 2021, ss.346-347, (Tam Metin Bildiri)

36. RELAPS/ REFRAKTER HODGKİN LENFOMA HASTALARINDA ALLOJENİK HEMATOPOETİK KÖK HÜCRE NAKLİ: TEK MERKEZ DENEYİMİ

13. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Antalya, Türkiye, 2 - 03 Nisan 2021, sa.52, ss.104-105, (Tam Metin Bildiri)

42. THE IMPACT OF PRETRANSPLANT IMMUNOMODULATORY DRUGS ON CMV REACTIVATION

8 45 th International Congress on Leukemia Lymphoma Myeloma, Ankara, Türkiye, 21 Mayıs 2021, cilt.38, sa.71, ss.1-81, (Tam Metin Bildiri)

43. The impact of pretransplant ımmunomodulatory drugs on cmv reactıvatıon

8th International congress on leukemia lymphoma myeloma, 2021, 21 Mayıs 2021, (Tam Metin Bildiri)

46. GRAFT VS HOST HASTALIĞINDA ALFA- 1 ANTİTRİPSİN DENEYİMİMİZ

46. Ulusal Hematoloji Kongresi , Antalya, Türkiye, 28 - 31 Ekim 2020, sa.283, ss.117-118, (Tam Metin Bildiri)

53. Treatment Of Thrombocytopenıa After Allogeneıc Stem Cell Transplantatıonwıth Eltrombopag

46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), 29 Ağustos - 01 Eylül 2020, (Tam Metin Bildiri)

54. Allogeneic hematopoietic stem cell transplantation for primary myelofibrosis: A single-center experience.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 29 - 31 Mayıs 2020, cilt.38, (Özet Bildiri) identifier

55. HEMORAJİK SİSTİT İÇİN YARGILANAN SİKLOFOSFAMİD SUÇSUZ BULUNDU: TEK MERKEZ 7 YILLIK DENEYİM

12. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Türkiye, 5 - 07 Mart 2020, (Tam Metin Bildiri)

56. AML TANISI İLE AKRABA DIŞI VERİCİDEN AHKHN YAPILAN HASTALARDA ATG KULLANIMININ NAKİL SONUÇLARINA ETKİSİ

12. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Türkiye, 5 - 07 Mart 2020, (Tam Metin Bildiri)

57. CD34 VE İMMUNEFEKTÖR HÜCRE SAYIMININ TRANSPLANTASYON SONUÇLARINA ETKİSİ

12. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Türkiye, 5 - 07 Mart 2020, (Tam Metin Bildiri)

58. CD34+ VE İMMUNEFEKTÖR HÜCRE SAYIMININ TRANSPLANTASYON SONUÇLARINA ETKİSİ

12. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Muğla, Türkiye, 5 - 07 Mart 2020, sa.159, ss.60-61, (Tam Metin Bildiri)

63. Large Granular Lymphocytosis and Its Impact on Long Term Clinical Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation: 14-Year Follow-up Data

61st Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Florida, Amerika Birleşik Devletleri, 7 - 10 Aralık 2019, cilt.134, (Özet Bildiri) identifier identifier

64. Which One, Generic Vs Original Glivec Is More Effective in Patients with Chronic Myeloid Leukemia?

61st Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Florida, Amerika Birleşik Devletleri, 7 - 10 Aralık 2019, cilt.134, (Özet Bildiri) identifier

69. Haploidentical stem cell transplantation may be an option for hematological malignancies in urgent conditions

45th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT), Frankfurt, Almanya, 24 - 27 Mart 2019, cilt.54, ss.382, (Özet Bildiri) identifier

70. Is mobilization with chemotherapy effect response in the multiple myeloma?

45th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT), Frankfurt, Almanya, 24 - 27 Mart 2019, cilt.54, ss.500, (Özet Bildiri) identifier

71. Can the drugs used before autologous hematopoietic stem cell transplantation have impact on CMV reactivation that results in decreased os in myeloma patients after ASCT?

45th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT), Frankfurt, Almanya, 24 - 27 Mart 2019, cilt.54, ss.505-506, (Özet Bildiri) identifier

73. SUCCESSFUL TREATMENT OF GRAFT FAILURE WITH SECOND ALLOGENEIC STEM CELL TRANSPLANTATION WITHOUT CONDITIONING REGIMEN

8th International Congress on Leukemia Lymphoma Myeloma, İstanbul, Türkiye, 2 - 04 Mayıs 2019, ss.75, (Tam Metin Bildiri)

78. CAN AUTOLOGOUS STEM CELL TRANSPLANTATION ABROGATE THE POOR PROGNOSIS ASSOCIATED WITH HIGH LDH?

7th International Congress on Leukemia Lymphoma Myeloma, İstanbul, Türkiye, 2 - 04 Mayıs 2019, ss.45, (Tam Metin Bildiri)

79. Pretransplant hemoglobin and serum creatinine levels correlate with progression free survival in myeloma patients undergoing autologous stem cell transplantation.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2019, cilt.37, (Özet Bildiri) identifier

80. Can autologous stem cell transplantation abrogate the poor prognosis associated with high LDH in myeloma patients?

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2019, cilt.37, (Özet Bildiri) identifier

83. CAN ELTROMBOPAG TREAT THE THROMBCYTOPENIA AFTER STEM CELL TRANSPLANTATION

7th International Congress on Leukemia Lymphoma, İstanbul, Türkiye, 2 - 04 Mayıs 2019, (Tam Metin Bildiri)

84. MULTİPLE MYELOM HASTALARINDA OTOLOG PERİFERİK KÖK HÜCRE NAKLİ ESNASINDA GELİŞEN NÖTROPENİK ATEŞ

11. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Antalya, Türkiye, 1 - 02 Mart 2019, sa.142, ss.130, (Tam Metin Bildiri)

88. Posttransplant Lenfositoz Önemli Bir Parametre midir?

11. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Türkiye, 1 - 03 Mart 2019, (Özet Bildiri)

89. Transplant Sonrası Trombositopenide Eltrombopag: Tek Merkez Deneyimimiz

11. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Antalya, Türkiye, 1 - 03 Mart 2019, (Tam Metin Bildiri)

95. Influence of Conditioning Regimens with Total Body Irradiation (TBI) on Graft Versus Host Disease and Graft Versus Leukemia Effect Following Donor Lymphocyte Infusions (DLI)

Transplant and Cell Therapy Meeting / Combined Annual Meetings of the American-Society-for-Blood-and-Marrow-Transplantation (ASBMT) and the Center-for-International-Blood-and-Marrow-Transplant-Research (CIBMTR), Texas, Amerika Birleşik Devletleri, 13 - 24 Şubat 2019, cilt.25, (Özet Bildiri) identifier

96. İmmun Trombositopeni (İTP) hastalarında ABO kan gruplarının birinci basamak tedavi yanıtına etkisi

TKBD Uluslararası Katılımlı Hematolojik Hastalıkların Tanı Ve İzleminde Laboratuvar Sempozyumu, Türkiye, 5 - 07 Nisan 2018, cilt.16, ss.44, (Özet Bildiri)

98. Comparision of Outcomes According to HLA Disparity in Acute Leukemia Patients: A Single Center Institution Experience

60th ASH Annual Meeting, san diego, Amerika Birleşik Devletleri, 29 Kasım - 05 Aralık 2018, cilt.132, ss.4673, (Tam Metin Bildiri)

99. Impact of ABO Mismatch on Outcomes of Allogeneic Hematopoietic Stem Cell Recipients: 30 Years of Experience with 1016 Patients

60th Annual Meeting of the American-Society-of-Hematology (ASH), California, Amerika Birleşik Devletleri, 1 - 04 Aralık 2018, cilt.132, (Özet Bildiri) identifier identifier

100. Donor Lymphocyte Infusions for Relapsed Hematological Malignancies after Allogeneic Hematopoietic Stem Cell Transplantation: Single Center Experience

60th Annual Meeting of the American-Society-of-Hematology (ASH), California, Amerika Birleşik Devletleri, 1 - 04 Aralık 2018, cilt.132, (Özet Bildiri) identifier

105. Fit Elderly Patients with aggressive lymphoma do not need dose reduction of conditioning regimen

44th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT), Lisbon, Portekiz, 18 - 21 Mart 2018, cilt.53, ss.272-273, (Özet Bildiri) identifier

107. Impact of Hepatitis B Core Antibody Seopositivity on the Liver Function Tests after Autologous Hematopoietic Stem Cell Transplantation For Multiple Myeloma

44th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT), Lisbon, Portekiz, 18 - 21 Mart 2018, cilt.53, ss.338, (Özet Bildiri) Sürdürülebilir Kalkınma identifier

108. Donor lymphocyte infusion after salvage chemotherapy in relapsed acute myeloblastic leukemia patients after allogeneic stem cell transplantation

44th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT), Lisbon, Portekiz, 18 - 21 Mart 2018, cilt.53, ss.161-162, (Özet Bildiri) identifier

109. Is post-transplant albumin a predictor of early transplant complications?

44th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT), Lisbon, Portekiz, 18 - 21 Mart 2018, cilt.53, ss.344-345, (Özet Bildiri) identifier

111. ALLOJENEİK KÖK HÜCRE NAKLİ SONRASI GELİŞENKARACİĞER SİNÜZOİDAL TIKANIKLIK SENDROM İNSİDANSIVE KLİNİK BULGULAR

10. ULUSAL KEMİK İLİĞİTRANSPLANTASYONU VEHÜCRESEL TEDAVİLER KONGRESİ, Antalya, Türkiye, 1 - 03 Mart 2018, (Özet Bildiri)

112. Allojeneik Hematopoetik Kök Hücre Nakli Sonrası Akut Myeloid Lösemi Nüksünün Yönetimi ve Prognozu

10. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Antalya, Türkiye, 1 - 03 Mart 2018, ss.126-127, (Özet Bildiri)

113. KEMOTERAPİ İLE MOBİLİZASYON MULTİPL MİYELOMDA YANITLARI ETKİLİYOR MU?

10. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, 01 Mart 2018, (Tam Metin Bildiri)

115. Ph Negatif ALL’de 1. Tam Remisyonda Yapılan Pekiştirme Tedavileri Nakil Sonrası Başarıyı Arttırır

10. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Antalya, Türkiye, 1 - 03 Mart 2018, (Özet Bildiri)

116. Age is Not an Important Factor for Autologous Peripheral Hematopoietic Stem Cell Mobilization and Collection in Patients with Multiple Myeloma

Blood and Marrow Transplantion Tandem Meetings of the Center-for-International-Blood-and-Marrow-Transplant-Research (CIBMTR) / American-Society-for-Blood-and-Marrow-Transplantation (ASBMT), Utah, Amerika Birleşik Devletleri, 21 - 25 Şubat 2018, cilt.24, (Özet Bildiri) identifier

118. AKUT GRAFT VERSUS HOST HASTALIĞI KLİNİK SONUÇLARI: TEK MERKEZ DENEYİMİ

10. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Antalya, Türkiye, 01 Mart 2018, (Özet Bildiri)

119. Age Is Not Important for Autologous Peripheral Hematopoietic Stem Cell Transplantation in Multiple Myeloma

59th Annual Meeting of the American-Society-of-Hematology (ASH), Georgia, Amerika Birleşik Devletleri, 9 - 12 Aralık 2017, cilt.130, (Özet Bildiri) identifier

120. Dilemma-High Response Rates Vs High Toxicity: Autologous Stem Cell Transplantation for Lymphoma

59th Annual Meeting of the American-Society-of-Hematology (ASH), Georgia, Amerika Birleşik Devletleri, 9 - 12 Aralık 2017, cilt.130, (Özet Bildiri) identifier

121. Engrafmanın Erken Belirteci: Büyük Boyanmamış Hücreler

43. Ulusal Hematoloji Kongresi, Antalya, Türkiye, 1 - 04 Kasım 2017, ss.53, (Özet Bildiri)

130. A single center experience with two decades of follow-up on patients with hairy cell leukemia.

53rd Annual Clinical Science Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Symposium on Old Targets, New Drugs - Her2 and MET, Illinois, Amerika Birleşik Devletleri, 2 - 07 Haziran 2017, cilt.35, (Özet Bildiri) identifier

131. Comparison of myeloablative vs reduced intensity conditioning regimens in stem cell transplantations for acute myeloid leukemia.

53rd Annual Clinical Science Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Symposium on Old Targets, New Drugs - Her2 and MET, Illinois, Amerika Birleşik Devletleri, 2 - 07 Haziran 2017, cilt.35, (Özet Bildiri) identifier

136. Evalauting peritransplant albümin decline as a predictor os acute graft versus host disease

43rdAnnual Meeting of the European Society for Blood and Marrow Transplantation, 26 - 29 Mart 2017, (Özet Bildiri)

152. Age as a decision factor for doing autologous stem cell transplantation in fit patients with myeloma and lymphoma.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 3 - 07 Haziran 2016, cilt.34, (Özet Bildiri) identifier

158. Positive Impact of Chronic Graft-Versus Host Disease on Survival in 928 Allogeneic Hematopoietic Stem Cell Transplant Recipients

57th Annual Meeting of the American-Society-of-Hematology, Florida, Amerika Birleşik Devletleri, 5 - 08 Aralık 2015, cilt.126, (Özet Bildiri) identifier

159. Comparison of Two Different Doses of Corticosteroid Premedication for Antithymocyte Globulin in Allogeneic Hematopoietic Stem Cell Transplantation

57th Annual Meeting of the American-Society-of-Hematology, Florida, Amerika Birleşik Devletleri, 5 - 08 Aralık 2015, cilt.126, (Özet Bildiri) identifier

160. Is Initial CD3+T Cell Dose in Donor Lymphocyte Infusion for Relapsed Hematological Malignancies a Prognostic Determinant?

57th Annual Meeting of the American-Society-of-Hematology, Florida, Amerika Birleşik Devletleri, 5 - 08 Aralık 2015, cilt.126, (Özet Bildiri) identifier

174. Extramedullary Relapse of Acute Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation Allo HSCT A Single Center Experience 41st Annual Meeting of the European Society for Blood and

(Allo-HSCT): A Single Center Experience. 41st Annual Meeting of the European Society for Blood and Marrow Transplantation, Istanbul, 22-25 Mayıs 2015., 22 - 25 Mayıs 2015, (Tam Metin Bildiri)

175. Allogeneic Stem Cell Transplantation for Hodgkin and non Hodgkin Lymphoma

5th International Congress on Lymphoma Leukemia Myeloma, İstanbul, Turkey, 21-23 May 2015. Turkish Society of Hematology, Proceedings & Abstract Book, abstract # 0109, poster # PS-101 pp 175., 21 - 23 Mayıs 2015

176. AUTOLOGOUS STEM CELL TRANSPLANTATION IN ELDERLY PATIENTS 60 YEARS WITH MYELOMA OR LYMPHOMA

5th International Congress on Lymphoma Leukemia Myeloma, İstanbul, Turkey, 21 - 23 Mayıs 2015, (Özet Bildiri)

177. Allogeneic stem cell transplantation results in our myelodysplastic syndrome (MDS) patients.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, Amerika Birleşik Devletleri, 29 Mayıs - 02 Haziran 2015, cilt.33, (Özet Bildiri) identifier

189. Prognosis of Acute Leukemia Patients with Active Disease Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT)

41st Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation, İstanbul, Türkiye, 22 - 25 Mart 2015, cilt.50, (Özet Bildiri) identifier

190. Different Doses of Anti-Thymocyte Globulin (ATG) in the Conditioning Regimen for Allogeneic Hematopoetic Stem Cell Transplantation

41st Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation, İstanbul, Türkiye, 22 - 25 Mart 2015, (Özet Bildiri) identifier

191. Do FMS-like Tyrosine Kinase 3 and Nucleophospmin 1 Gene Mutations Really Effect Survival in Acute Myeloid Leukemia ?

56th Annual Meeting of the American-Society-of-Hematology, San-Francisco, Kostarika, 6 - 09 Aralık 2014, cilt.124, (Özet Bildiri) identifier

192. Clinical Reflection of Immunophenotyping in Paroxysmal Nocturnal Hemoglobinuria: Experience of a Single Center

56th Annual Meeting of the American-Society-of-Hematology, San-Francisco, Kostarika, 6 - 09 Aralık 2014, cilt.124, (Özet Bildiri) identifier

193. Treatment Approaches in Acute Leukemia Patients Relapsing Following Allogeneic Hematopoietic Stem Cell Transplantation

56th Annual Meeting of the American-Society-of-Hematology, San-Francisco, Kostarika, 6 - 09 Aralık 2014, cilt.124, (Özet Bildiri) identifier

194. Fertility in Our Allogeneic Hematopoietic Stem Cell Transplant Patients

56th Annual Meeting of the American-Society-of-Hematology, San-Francisco, Kostarika, 6 - 09 Aralık 2014, cilt.124, (Özet Bildiri) identifier

195. Is the Chronic Myeloproliferative Disease Prognosis Really Different in Geriatric Patients?

56th Annual Meeting of the American-Society-of-Hematology, San-Francisco, Kostarika, 6 - 09 Aralık 2014, cilt.124, (Özet Bildiri) identifier

196. Is R-CODOX-M/IVAC Inferior to Other Regimens in Burkitt's Lymphoma: A Single Center Experience

56th Annual Meeting of the American-Society-of-Hematology, San-Francisco, Kostarika, 6 - 09 Aralık 2014, cilt.124, (Özet Bildiri) identifier

202. OTOLOG HEMATOPOETİK KÖK HÜCRE NAKLİ SONRASINDA GELİŞEN BİR CMV RETİNİT VAKASI

8. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, 06 Mart 2014, (Özet Bildiri)

203. Management of Hemorrhagic Cystitis after Allogeneic Hematopoietic Stem Cell Transplantation

BMT Tandem Meetings, Texas, Amerika Birleşik Devletleri, 26 Şubat - 02 Mart 2014, cilt.20, (Özet Bildiri) Creative Commons License identifier

204. Comparison Of Flow Cytometric and Clinical Findings In Patients With Paroxysmal Nocturnal Hemoglobinuria

55th Annual Meeting of the American-Society-of-Hematology, Louisiana, Amerika Birleşik Devletleri, 7 - 10 Aralık 2013, cilt.122, (Özet Bildiri) identifier

209. European experience of allogeneic hematopoietic stem cell transplantation for metastatic renal carcinoma: On behalf of the French ITAC group and the EBMT solid tumour working party

32nd Annual Meeting of the American-Society-for-Blood-and-Marrow-Transplantation, Hawaii, Amerika Birleşik Devletleri, 16 - 20 Şubat 2006, cilt.12, ss.21, (Özet Bildiri) identifier

210. Allogeneic haematopoietic cell transplantation in acute myeloblastic laeukemia: Ibni Sina experience (1989-2004)

31st Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation/21st Meeting of the EBMT-Nurses-Group/4th Meeting of the EBMT-Data-Management-Group, Prague, Çek Cumhuriyeti, 20 - 23 Mart 2005, cilt.35, (Özet Bildiri) identifier

211. The comparison of myeloablative versus reduced intensity conditioning regimen in ABO mismatched allogeneic hematopoietic cell transplantation.

46th Annual Meeting of the American-Society-of-Hematology, California, Amerika Birleşik Devletleri, 4 - 07 Aralık 2004, cilt.104, (Özet Bildiri) identifier

212. Allogeneic hemapoietic progenitor cell collection using four different cell separators: A retrospective comparative analysis.

46th Annual Meeting of the American-Society-of-Hematology, California, Amerika Birleşik Devletleri, 4 - 07 Aralık 2004, cilt.104, (Özet Bildiri) identifier

213. Prognostic factors for survival in renal cell cancer patients undergoing allogeneic stem cell transplantation: A report from the EBMT Solid Turnouts Working Party

40th Annual Meeting of the American-Society-of-Clinical-Oncology, Louisiana, Amerika Birleşik Devletleri, 5 - 08 Haziran 2004, cilt.22, (Özet Bildiri) Sürdürülebilir Kalkınma identifier

214. High-dose thiotepa, melphalan and carboplatin followed by autologous peripheral blood stem cell transplantation in patients with lymphoma - a retrospective evaluation

30th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation/20th Meeting of the EBMT-Nurses-Group/3rd Meeting of the EBMT-Data-Management-Group, Barcelona, İspanya, 28 - 31 Mart 2004, cilt.33, (Özet Bildiri) identifier

216. Comparison of three conditioning regimens used in high-dose therapy of malign lymphomas: CBV-ICE-CTM

29th Annual Meeting of the European Group for Blood and Marrow Transplantation/19th Meeting of the EBMT Nurses Group/2nd Meeting of the EBMT Data Management Group, İstanbul, Türkiye, 23 - 26 Mart 2003, cilt.31, (Özet Bildiri) identifier
Kitaplar 1

1. Future Perspectives for Haploidentical Stem Cell Transplantation

Haploidentical Stem Cell Transplantation: An Emerging Treatment Modality, TANER DEMİRER, Editör, Humana Press, CHAM, ss.189-198, 2017
Metrikler

Yayın

413

Yayın (WoS)

212

Yayın (Scopus)

171

Atıf (WoS)

4942

H-İndeks (WoS)

37

Atıf (Scopus)

5645

H-İndeks (Scopus)

42

Tez Danışmanlığı

1

Açık Erişim

44
BM Sürdürülebilir Kalkınma Amaçları